Nephrology
Guidelines
New guidelines address diabetes management in kidney disease
The Kidney Disease: Improving Global Outcomes synopsis document is aimed at primary care physicians and nonnephrology specialists, as well as...
From the Journals
New eGFR equation ‘less biased’ by age, kidney function; some disagree
The European Kidney Function Consortium equation surpasses existing equations by "resulting in generally lower bias across the spectrum of age and...
Conference Coverage
Novel drug slows progression of diabetic kidney disease
Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular events, with good...
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Conference Coverage
Survival after kidney transplantation lags in diabetes patients
Overall U.S. survival after kidney transplantation rose during 2000-2018, but less so in patients with type 1 or type 2 diabetes.
From the Journals
Late-onset neutropenia more common than expected in patients on rituximab
“Even though most [cases] are incidental and can be self-limiting, some can be severe and associated with sepsis.”
From the Journals
Deaths sky high in hospitalized COVID patients with kidney injury
“We may be facing an epidemic of post–COVID-19 kidney disease and that, in turn, could mean much greater numbers of patients who require kidney...
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
Feature
SGLT2 inhibitors have a breakout year
Latest News
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
The findings are based on the use of three different SGLT2 inhibitors in Canada and the United Kingdom.